(Q46645277)

English

Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study

scientific article published in January 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16094658

Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study (English)

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16094658

author name string

E Baca Baldomero

1

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16094658

J Giner Ubago

2

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16094658

C Leal Cercós

3

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16094658

J Vallejo Ruiloba

4

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16094658

C García Calvo

5

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16094658

R Prieto López

6

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16094658

publication date

1 January 2005

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16094658

Depression and Anxiety

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16094658

22

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16094658

68-76

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16094658

2

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16094658

Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20080

21 January 2018

The definition and operational criteria for treatment outcome of major depressive disorder. A review of the current research literature

1 reference

https://api.crossref.org/works/10.1002%2FDA.20080

21 January 2018

Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study

1 reference

https://api.crossref.org/works/10.1002%2FDA.20080

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine

1 reference

https://api.crossref.org/works/10.1002%2FDA.20080

7 January 2021

based on heuristic

inferred from DOI database lookup

Psychotic symptoms in combat-related posttraumatic stress disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.20080

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.20080

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20080

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20080

7 January 2021

based on heuristic

inferred from DOI database lookup

Systematic review and guide to selection of selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FDA.20080

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20080

7 January 2021

based on heuristic

inferred from DOI database lookup

Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features

1 reference

https://api.crossref.org/works/10.1002%2FDA.20080

7 January 2021

based on heuristic

inferred from DOI database lookup

The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group

1 reference

https://api.crossref.org/works/10.1002%2FDA.20080

7 January 2021

based on heuristic

inferred from DOI database lookup

Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FDA.20080

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of venlafaxine in depressive illness in general practice

1 reference

https://api.crossref.org/works/10.1002%2FDA.20080

7 January 2021

based on heuristic

inferred from DOI database lookup

Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study

1 reference

https://api.crossref.org/works/10.1002%2FDA.20080

7 January 2021

based on heuristic

inferred from DOI database lookup

Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20080

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronological milestones to guide drug change. When should clinicians switch antidepressants?

1 reference

https://api.crossref.org/works/10.1002%2FDA.20080

7 January 2021

based on heuristic

inferred from DOI database lookup

A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.20080

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20080

7 January 2021

based on heuristic

inferred from DOI database lookup

Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FDA.20080

7 January 2021

based on heuristic

inferred from DOI database lookup

A meta-analysis of the effects of venlafaxine on anxiety associated with depression.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20080

7 January 2021

based on heuristic

inferred from DOI database lookup

A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20080

7 January 2021

based on heuristic

inferred from DOI database lookup

Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group

1 reference

https://api.crossref.org/works/10.1002%2FDA.20080

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.20080

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire

1 reference

https://api.crossref.org/works/10.1002%2FDA.20080

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group

1 reference

https://api.crossref.org/works/10.1002%2FDA.20080

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20080

7 January 2021

based on heuristic

inferred from DOI database lookup

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FDA.20080

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia

1 reference

https://api.crossref.org/works/10.1002%2FDA.20080

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/DA.20080

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16094658

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16094658

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46645277&oldid=2123773993"